leisure time -WSS

leisure time

author：explore 2025-08-17 00:02:31 - browse：2194

People in business and medical wardrobe in a table discussion — coverage from STAT — Adobe

R1 RCM, a large publicly traded technology company that helps hospitals and physicians collect money from insurers and patients, may be going private.

Private equity firm New Mountain Capital has offered to purchase R1 for $13.75 per share, or roughly $5.8 billion in cash, according to new financial disclosures filed Monday. New Mountain Capital is R1’s second-largest investor, owning nearly one-third of the company’s shares.

In response to the offer, R1 asked New Mountain Capital to “engage in good faith discussions” with its largest investor — a partnership between Ascension, the large Catholic hospital system, and private equity firm TowerBrook Capital Partners. New Mountain Capital has since held several in-person meetings with Ascension and TowerBrook throughout February, but maintained its original offer for R1. No deal has been finalized yet.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Malaria cases in Florida and Texas: Here’s what you need to know
Next article： John Green on his newest strategy for fighting tuberculosis

hotspot

explore

WSS

Boston's new lab space is opening empty

Congress extends some pandemic preparedness programs

The Karikó problem: Lessons for funding basic research

WHO recommends second malaria vaccine

Pushing for an NIH office for post

RSV injection headlines need to be accurate for good uptake

hotspot

leisure time

focus

Cancer drug shortages should be causing more outrage

New oral drug delivery patch is modeled after octopus tentacles

State Dept. review finds Biden bears some blame for Afghanistan failures

Lawsuit highlights wrinkle for disputes over surprise medical bills

As demand for Covid shots wanes, Moderna seeks its next success

How many hemophilia patients actually want gene therapy?

Psychedelics group wrestles with new pharma identity

Readout Newsletter: Bristol, Sangamo, Gilead, and more

In Memoriam: Notable people who died in 2023

Flu, Covid vaccination rates decline, new survey data show

explore

Experts study whether long Covid risk adds up with each reinfection

UCLA team creates talking throat patch for voice disorders

The biotech scorecard for Q4: 16 stock

Amylyx ALS drug fails trial: Relyvrio patients react with fear, worry

Lawsuit highlights wrinkle for disputes over surprise medical bills

Amid AI frenzy, a top HHS official's quest to create safeguards

focus

hotspot

explore

explore